Neptune Wellness Solutions (TSE:NEPT) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Profitability
This table compares Neptune Wellness Solutions and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Neptune Wellness Solutions | N/A | N/A | N/A |
ImmunoPrecise Antibodies | N/A | N/A | N/A |
Valuation and Earnings
This table compares Neptune Wellness Solutions and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Neptune Wellness Solutions | C$52.78 million | 4.89 | C$-223,415,550.00 | C($1.35) | -1.16 |
ImmunoPrecise Antibodies | C$17.18 million | 15.08 | C$-4,082,906.00 | C($0.21) | -63.46 |
ImmunoPrecise Antibodies has lower revenue, but higher earnings than Neptune Wellness Solutions. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Neptune Wellness Solutions and ImmunoPrecise Antibodies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Neptune Wellness Solutions | 0 | 0 | 1 | 0 | 3.00 |
ImmunoPrecise Antibodies | 0 | 0 | 0 | 0 | N/A |
Neptune Wellness Solutions currently has a consensus price target of C$4.63, suggesting a potential upside of 196.47%. Given Neptune Wellness Solutions' higher possible upside, equities analysts clearly believe Neptune Wellness Solutions is more favorable than ImmunoPrecise Antibodies.
Summary
Neptune Wellness Solutions beats ImmunoPrecise Antibodies on 4 of the 7 factors compared between the two stocks.